Literature DB >> 27044389

miR-17-92 cluster components analysis in Burkitt lymphoma: overexpression of miR-17 is associated with poor prognosis.

Marcela Cristina Robaina1,2, Roberta Soares Faccion1, Luciano Mazzoccoli1, Lidia Maria M Rezende3, Eduardo Queiroga4, Carlos E Bacchi4, Andrei Thomas-Tikhonenko2,5, Claudete Esteves Klumb6,7.   

Abstract

Burkitt lymphoma (BL) is an aggressive B cell lymphoma characterized by the reciprocal translocation of the c-Myc gene with immunoglobulin genes. Recently, MYC has been shown to maintain the neoplastic state via the miR-17-92 microRNA cluster that suppresses chromatin regulatory genes and the apoptosis regulator Bim. However, the expression and prognostic impact of miR-17-92 members in pediatric BL (pBL) are unknown. Therefore, we investigated miR-17, miR-19a, miR-19b, miR-20, and miR-92a expression and prognostic impact in a series of 41 pBL samples. In addition, Bim protein expression was evaluated and compared to miR-17, miR-19a, miR-19b, miR-20, and miR-92a levels and patient outcomes. The expression of miR-17-92 members was evaluated by qPCR and Bim protein by immunohistochemistry. Log-rank test was employed to assess prognostic impact. We found that upregulated expression of miR-17 and miR-20a correlates with lack of pro-apoptotic Bim expression. Patients bearing tumors with upregulated miR-17 displayed decreased overall survival (OS), and multivariate analysis revealed that miR-17 was a significant predictor of shortened OS. Using hairpin inhibitors, we showed that inhibition of miR-17 resulted in enhanced Bim expression in a BL cell line overexpressing the miR-17-92 cluster. Our results describe for the first time miR-17, miR-19a, miR-19b, miR-20a, and miR-92a expression profiles in pBL. The prognostic impact of miR-17 should be validated in a larger series, and may provide new therapeutic avenues in the era of anti-miRNA therapy research. Additional functional studies are further required to understand the specific role of miR-17-92 cluster members in BL.

Entities:  

Keywords:  Bim; Burkitt lymphoma; MYC; Prognosis; miR-17 and miR-20a family; miR-17-92 cluster

Mesh:

Substances:

Year:  2016        PMID: 27044389     DOI: 10.1007/s00277-016-2653-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  18 in total

1.  MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells.

Authors:  Luciano Mazzoccoli; Marcela Cristina Robaina; Alexandre Gustavo Apa; Martin Bonamino; Luciana Wernersbach Pinto; Eduardo Queiroga; Carlos E Bacchi; Claudete Esteves Klumb
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-09       Impact factor: 4.553

2.  Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age.

Authors:  Birgit Burkhardt; Ulf Michgehl; Jonas Rohde; Tabea Erdmann; Philipp Berning; Katrin Reutter; Marius Rohde; Arndt Borkhardt; Thomas Burmeister; Sandeep Dave; Alexandar Tzankov; Martin Dugas; Sarah Sandmann; Falko Fend; Jasmin Finger; Stephanie Mueller; Nicola Gökbuget; Torsten Haferlach; Wolfgang Kern; Wolfgang Hartmann; Wolfram Klapper; Ilske Oschlies; Julia Richter; Udo Kontny; Mathias Lutz; Britta Maecker-Kolhoff; German Ott; Andreas Rosenwald; Reiner Siebert; Arend von Stackelberg; Brigitte Strahm; Wilhelm Woessmann; Martin Zimmermann; Myroslav Zapukhlyak; Michael Grau; Georg Lenz
Journal:  Nat Commun       Date:  2022-07-06       Impact factor: 17.694

Review 3.  Prognostic role of miR-17-92 family in human cancers: evaluation of multiple prognostic outcomes.

Authors:  Feifei Liu; Feng Zhang; Xiangyu Li; Qi Liu; Wei Liu; Peng Song; Ziying Qiu; Yu Dong; Hao Xiang
Journal:  Oncotarget       Date:  2017-07-08

4.  Micro RNA-19a interferes with IL-10 expression in peripheral dendritic cells of patients with nasal polyposis.

Authors:  Xiang-Qian Luo; Jian-Bo Shao; Rui-Di Xie; Lu Zeng; Xiao-Xi Li; Shu-Qi Qiu; Xiao-Rui Geng; Li-Tao Yang; Lin-Jing Li; Da-Bo Liu; Zhi-Gang Liu; Ping-Chang Yang
Journal:  Oncotarget       Date:  2017-07-25

5.  Oncogenic miR-19a and miR-19b co-regulate tumor suppressor MTUS1 to promote cell proliferation and migration in lung cancer.

Authors:  Yuanyuan Gu; Shuoxin Liu; Xiaodan Zhang; Guimin Chen; Hongwei Liang; Mengchao Yu; Zhicong Liao; Yong Zhou; Chen-Yu Zhang; Tao Wang; Chen Wang; Junfeng Zhang; Xi Chen
Journal:  Protein Cell       Date:  2017-03-31       Impact factor: 14.870

6.  Prognostic value of high-expression of miR-17-92 cluster in various tumors: evidence from a meta-analysis.

Authors:  Kaiping Zhang; Li Zhang; Meng Zhang; Yin Zhang; Dengxin Fan; Jiabin Jiang; Liqin Ye; Xiang Fang; Xianguo Chen; Song Fan; Min Chao; Chaozhao Liang
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

7.  MicroRNA-17 and the prognosis of human carcinomas: a systematic review and meta-analysis.

Authors:  Chengzhi Huang; Mengya Yu; Xueqing Yao
Journal:  BMJ Open       Date:  2018-05-31       Impact factor: 2.692

8.  Expression Profiling Analysis Reveals Key MicroRNA-mRNA Interactions in Early Retinal Degeneration in Retinitis Pigmentosa.

Authors:  Ander Anasagasti; Maitane Ezquerra-Inchausti; Olatz Barandika; Maider Muñoz-Culla; María M Caffarel; David Otaegui; Adolfo López de Munain; Javier Ruiz-Ederra
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-05-01       Impact factor: 4.799

9.  MiR-17 and miR-93 Promote Tumor Progression by Targeting p21 in Patients with Chordoma.

Authors:  Wei Dong; Jingwu Li; Xiaoliu Dong; Wenjian Shi; Yu Zhang; Yongliang Liu
Journal:  Onco Targets Ther       Date:  2021-05-12       Impact factor: 4.147

10.  Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.

Authors:  Maria Bhatti; Thomas Ippolito; Cory Mavis; Juan Gu; Mitchell S Cairo; Megan S Lim; Francisco Hernandez-Ilizaliturri; Matthew J Barth
Journal:  Oncotarget       Date:  2018-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.